Fundamental Analysis of Galera Therapeutics Inc - Growth / Value Index


GRTX - Valuation Highlights

Valuation Analysis

   Book Value in last 3 years is trending up
   Tsr Value Index - Poor Score of 23.44
   Book value is negative
Valuation Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Price to Earning -50.62 -137.52 -146759.60 %
Price to Book -19.14 -73.05 -136782.56 % -0.087
Price to Sales 26318.99 0 0 %
Enterprise Value to EBITDA Multiple 0.163 -172.08 -541216.31 %


GRTX - Profitability Highlights

Profitability Analysis

   Strong Return On Capital Employed of 53.12
   Company Earning excess return
   Company's Net Profit is increasing for last 5 Quarters
   Company's Profit Before Tax is increasing for last 5 Quarters
   Tsr Profitability Index - Very Poor Score of 5.00
   Very Low Dividend Yield of 0 %
   Negative Net profit for last two years
   Company Net profit is Negative for last 5 Quarters
   In the last three years, the company has given poor Net Margin
   In the last three years, the company has given poor Returns on Equity
   In the last three years, the company has given poor Returns on Assets
Profitability Key Ratios
Ratio TTM Latest FY Yoy Change MRQ
Return On Equity 0 0 0 % 0
Return On Asset -119.42 -266.57 -88.66 % -22.29
Net Profit Margin -51992.05 0 0 % 0
Operating Profit Margin -42780.68 0 0 % 0
EBITDA Margin -44680.68 0 0 % 0


Highlights
Market Cap11699.76 K
Enterprise Value-6424.24 K
Price/Book TTM-19.14
Outstanding Share54392.20 K
Float/ Outstanding Share66.62%
Dividend Yield0 %
Share Holding
Guru Numbers
Price/Graham No0
Peter Lynch Ratio0
Piotroski F Score3.00
Altman Z Score-29.66
Sloan Ratio-0.796
Peter Lynch Fair Value0


GRTX - Growth Highlights

Growth Analysis

   Annual sales of the company is increased for three years in a row
   Tsr Growth Index - Very Poor Score of 5.00
   Quarterly sales in last 5 Quarter is trending down
   Annual sales in last 3 years is trending down
   Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
Field TTM YoY Growth QoQ Growth
Revenue 88000.00 % 100.00 %
Gross Profit -248000.00 127.19 % 95.81 %
EBITDA -39319.00 K 10.13 % 7.74 %
Net Profit -45753.00 K 11.99 % 21.59 %
EPS -0.0042 99.93 % NA


GRTX - Stability Highlights

Stability Analysis

   Cash ratio of 3.68
   Tsr Stability Index - Very Poor Score of 5.00
   Altman Z Score of -29.67 suggest high risk
   Company is unable to generate enough free cash to support the business.
   Interest Coverage of -3.97
Stability Key Ratios
Ratio Latest FY Yoy Change MRQ
Debt to Equity Ratio -0.0010 -151.57 % -0.0010
Cash Ratio 3.68 55.95 %
Quick Ratio 0 0 % 7.54
Shareholders Equity -501.84 -102.41 %
Debt to EBITDA -0.0024 -174.47 %


Historical Valuation Ratios of Galera Therapeutics Inc

Historical Valuation Ratios
Loading ...

Historical Profitability Ratios of Galera Therapeutics Inc

Historical Profitability Ratios
Loading ...

Historical Efficiency Ratios of Galera Therapeutics Inc

Historical Efficiency Ratios
Loading ...

Historical Solvency Ratios of Galera Therapeutics Inc

Historical Solvency Ratios
Loading ...


Note : All Data Generated at the End of Trading Hours (EOD Data)